Malarone

Atovaquone/proguanil, the active ingredient in Malarone, is an antimalarial combination presented as a 250 mg atovaquone / 100 mg proguanil hydrochloride tablet for oral use. It is indicated for the prevention of malaria infection and for the treatment of acute, uncomplicated malaria caused by Plasmodium falciparum, Plasmodium vivax, and other species in travelers and patients at risk.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Malarone is used within the antimalarial therapeutic class to prevent and treat malaria caused by susceptible Plasmodium species. - Prevention of malaria (chemoprophylaxis): provides protective effect for travelers to endemic areas. - Treatment of acute uncomplicated malaria: used to clear infection caused by susceptible Plasmodium species. - Post‑exposure prophylaxis: administered after possible exposure to prevent disease development. - Treatment of chloroquine‑resistant malaria: effective against strains resistant to older agents.

Malarone may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset that may occur during treatment. - Headache: mild to moderate headache reported by some patients. - Abdominal discomfort: includes stomach pain or cramps. - Loss of appetite: reduced desire to eat during therapy. - Metallic taste: transient taste disturbance.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hematologic abnormalities: including neutropenia or thrombocytopenia.

Before initiating Malarone, consider the following safety measures. - Assess contraindications: avoid in patients with known hypersensitivity to any component. - Evaluate pregnancy status: safety not established; use only if benefits outweigh potential risks. - Monitor liver function: consider baseline and periodic testing in patients with hepatic disease. - Review concomitant medications: check for interactions that may affect drug efficacy. - Advise on adherence: take with food to improve absorption. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Malarone can interact with several medicines; awareness helps maintain therapeutic effectiveness.

Major Interactions (Avoid): - Rifampin: reduces plasma concentrations of atovaquone, compromising efficacy. - Cimetidine: may increase atovaquone levels, raising risk of toxicity. - Antacids containing aluminum or magnesium: decrease absorption of atovaquone, lowering effectiveness.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Protease inhibitor antiretrovirals: may alter proguanil metabolism, affecting drug levels. - Macrolide antibiotics (e.g., erythromycin): may increase proguanil concentrations, necessitating clinical observation.